help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fritsche, A.
Right arrow Articles by Stumvoll, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritsche, A.
Right arrow Articles by Stumvoll, M.
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 10 4822-4825
Copyright © 2001 by The Endocrine Society


Other Original Articles

The Prevalent Gly1057Asp Polymorphism in the Insulin Receptor Substrate-2 Gene Is Not Associated with Impaired Insulin Secretion

Andreas Fritsche, Alexander Madaus, Walter Renn, Otto Tschritter, Anna Teigeler, Melanie Weisser, Elke Maerker, Fausto Machicao, Hans Häring and Michael Stumvoll

Medizinische Klinik, Abteilung für Endokrinologie, Stoffwechsel und Pathobiochemie, Eberhard-Karls-Universität, Tübingen, Germany

Address all correspondence and requests for reprints to: Dr. Michael Stumvoll, Medizinische Universitätsklinik, Otfried-Müller-Str. 10, D-72076 Tübingen, Germany. E-mail: Michael.Stumvoll{at}med.uni-tuebingen.de

Abstract

Disruption of the insulin receptor substrate-2 was shown to cause type 2 diabetes in mice. This could be largely attributed to abnormal ß-cell development. In humans, a prevalent polymorphism in insulin receptor substrate-2 (Gly1057Asp) was not found be associated with type 2 diabetes in linkage and association studies. We tested the hypothesis that an extreme challenge of the ß cell might reveal subtle abnormalities in carriers of this polymorphism undetected by conventional insulin secretion tests. Therefore, in addition to assessing ß-cell function by oral glucose tolerance testing (n = 318, normal glucose tolerance), we measured the secretory response to maximal stimulation by hyperglycemia (10 mM), glucagon-like peptide-1, and arginine administered in an additive fashion (n = 77, nondiabetic). The allelic frequency of the Asp allele was ~37%. Neither the ß-cell function indices from the oral glucose tolerance test nor the secretory response during the hyperglycemic clamp differed measurably between carriers and controls. Moreover, maximal plasma C-peptide concentrations in response to the combined glucose, glucagon-like peptide-1, and arginine stimulus was not different between Gly/Gly (10,745 ± 1,186 pmol/liter) and X/Asp (10,800 ± 490 pmol/liter, P = 0.99). In conclusion, our findings strongly suggest that the Gly1057Asp polymorphism in insulin receptor substrate-2 is not associated with ß-cell dysfunction. The normal maximal insulin secretory response makes it unlikely that this common polymorphism results in abnormal ß-cell development.




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
W.-D. Li, C. Dong, D. Li, C. Garrigan, and R. A. Price
A genome scan for serum triglyceride in obese nuclear families
J. Lipid Res., March 1, 2005; 46(3): 432 - 438.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
N. Stefan, P. Kovacs, M. Stumvoll, R. L. Hanson, A. Lehn-Stefan, P. A. Permana, L. J. Baier, P. A. Tataranni, K. Silver, and C. Bogardus
Metabolic Effects of the Gly1057Asp Polymorphism in IRS-2 and Interactions With Obesity
Diabetes, June 1, 2003; 52(6): 1544 - 1550.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
O. Tschritter, A. Fritsche, F. Shirkavand, F. Machicao, H. Haring, and M. Stumvoll
Assessing the Shape of the Glucose Curve During an Oral Glucose Tolerance Test
Diabetes Care, April 1, 2003; 26(4): 1026 - 1033.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. C. Bonadonna, M. Stumvoll, A. Fritsche, M. Muggeo, H. Haring, E. Bonora, and T. W. van Haeften
Altered Homeostatic Adaptation of First- and Second-Phase {beta}-Cell Secretion in the Offspring of Patients With Type 2 Diabetes: Studies With a Minimal Model to Assess {beta}-Cell Function
Diabetes, February 1, 2003; 52(2): 470 - 480.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. D'Alfonso, M. A. Marini, L. Frittitta, R. Sorge, S. Frontoni, O. Porzio, L. M. Mariani, D. Lauro, S. Gambardella, V. Trischitta, et al.
Polymorphisms of the Insulin Receptor Subtrate-2 in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 317 - 322.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
L. M. 't Hart, G. Nijpels, J. M. Dekker, J. A. Maassen, R. J. Heine, and T. W. van Haeften
Variations in Insulin Secretion in Carriers of Gene Variants in IRS-1 and -2
Diabetes, March 1, 2002; 51(3): 884 - 887.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society